Intellia to Present HAELO Trial Data at EAACI Congress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 02 2025
0mins
Source: PRnewswire
Intellia Therapeutics' stock fell 12.14% as it crossed below the 5-day SMA amid a broader market decline, with the Nasdaq-100 down 4.49% and the S&P 500 down 2.31%.
The company announced it will present data from the HAELO clinical trial at the 2026 EAACI Annual Congress, showcasing its CRISPR gene editing therapy, lonvo-z, which aims to improve treatment standards for hereditary angioedema (HAE). The presentation is scheduled for June 13 and is expected to attract significant attention, potentially enhancing Intellia's market position. Additionally, a poster presentation will address treatment barriers faced by HAE patients in Europe, aiming to raise awareness and promote better treatment options, which could lead to future collaborations.
This presentation comes at a time when the market is experiencing significant volatility, and while the stock has faced a sharp decline, the upcoming data presentation could provide a catalyst for recovery if the results are well-received.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTLA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTLA
Wall Street analysts forecast NTLA stock price to fall
22 Analyst Rating
9 Buy
12 Hold
1 Sell
Moderate Buy
Current: 17.840
Low
4.00
Averages
16.50
High
54.00
Current: 17.840
Low
4.00
Averages
16.50
High
54.00
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intellia Therapeutics Shares Surge 83% Amid Strong Clinical Progress
- Clinical Trial Success: Intellia Therapeutics' lonvo-z demonstrated an 87% reduction in attacks and 62% of patients were attack-free in phase 3 trials, indicating its potential as an effective treatment for hereditary angioedema, which could significantly enhance the company's market position in biotechnology.
- Significant Market Potential: While the market opportunity for lonvo-z is limited, the potential patient population for nex-z targeting ATTR amyloidosis could reach 50,000, and increasing diagnosis rates due to an aging population suggest substantial revenue growth opportunities for Intellia in global markets.
- Strong Financial Position: Intellia ended Q1 with $517.2 million in cash and equivalents and raised approximately $207 million through a secondary stock offering, with management confident that this funding will sustain operations until 2028, bolstering investor confidence in its future growth.
- Notable Risks: Despite the positive outlook from lonvo-z's success, nex-z faced a clinical hold from the FDA due to safety concerns, and the high costs associated with gene-editing therapies may deter insurance coverage, making Intellia's stock a risky investment suitable only for those with a high risk tolerance.
See More
Investor Sentiment Divided in Healthcare Sector
- High Short Interest: As of late June 2026, Intellia Therapeutics (NTLA) and SELLAS Life Sciences Group (SLS) exhibit short interests of 36.01% and 34.06%, respectively, indicating strong bearish sentiment that could pressure stock prices and hinder their ability to raise capital.
- Defensive Stocks Steady: In stark contrast, established pharmaceutical giants like Eli Lilly (LLY) and Johnson & Johnson (JNJ) maintain short interests around 1%, reflecting investor confidence that may help them remain stable amid market volatility, potentially attracting more conservative investors.
- Healthcare Sector Underperformance: Despite a robust 9.55% year-to-date rally in the S&P 500, the Health Care Select Sector SPDR® Fund (XLV) has only gained 2.49%, highlighting the sector's lagging performance which could dampen long-term investor confidence in healthcare stocks.
- Short Interest and Market Dynamics: Hims & Hers Health (HIMS) and Beam Therapeutics (BEAM) show short interests of 29.35% and 28.44%, respectively, suggesting cautious investor sentiment towards their growth prospects, which may challenge their financing and market expansion efforts.
See More
Short Sellers' Dilemma and Opportunities
- Short Seller Focus: There is a divergence in market sentiment regarding short sellers, with some analysts believing certain companies are in trouble while others see them as prime candidates for a short squeeze, reflecting the complexity of market emotions.
- Ondas Acquisition Activity: Ondas Inc. acquired Cyberhawk for $125 million, and although this transaction barely registered on Wall Street's radar, the establishment of its M&A moat could support future growth for the company.
- CleanSpark Risk Assessment: CleanSpark's pivot towards artificial intelligence is viewed as high-risk, leading to insufficient market confidence in its future performance, which may negatively impact its stock price and investor sentiment.
- Vibrant Market Discussion: Investors are actively discussing the pros and cons of short selling in the comments section, showcasing the high level of interest in short trading strategies and the clash of differing viewpoints.
See More
Intellia Therapeutics Advances Gene Editing Treatment with Promising Phase 3 Results
- Clinical Trial Success: Intellia Therapeutics' lonvo-z demonstrated an 87% reduction in attacks during phase 3 trials, with 62% of patients remaining completely attack-free, indicating the treatment's effectiveness in hereditary angioedema (HAE) and potentially significant market opportunities for the company.
- Regulatory Submission Progress: The company has initiated a rolling submission for lonvo-z, aiming to complete it in the second half of the year, and if approved, plans to launch the product in the first half of next year, which could provide a new revenue stream and boost market confidence.
- Optimistic Market Expectations: Wall Street anticipates Intellia's stock price will rise by 70% over the next 12 months, from the current $15.25 to $26, reflecting investor confidence in the company's gene editing technology and its commercialization potential.
- Long-Term Growth Potential: Despite an 80% decline in stock price over the past five years, Intellia's progress with lonvo-z and a second candidate in late-stage trials positions the company to transition into a commercial-stage biotech, opening new avenues for revenue growth.
See More
Intellia Therapeutics Advances Promising New Therapy
- Clinical Trial Success: Intellia Therapeutics achieved an impressive 87% reduction in attack frequency in its phase 3 trial for hereditary angioedema (HAE) with lonvo-z, with 62% of patients remaining completely attack-free during the evaluation period, demonstrating the efficacy and market potential of its technology.
- Regulatory Filing Progress: The company has initiated a rolling submission for lonvo-z, aiming to complete its FDA application in the second half of the year, which will expedite the review process and potentially lead to a market launch in the first half of next year, significantly boosting revenue prospects.
- Optimistic Market Expectations: Wall Street analysts forecast a 70% increase in Intellia's stock over the next 12 months, with a target price exceeding $26, reflecting confidence in the company's technology and product outlook, despite an 80% decline in stock price over the past five years.
- Significant Technological Potential: Intellia's gene editing technology shows promise not only in HAE treatment but also in other serious diseases like transthyretin amyloidosis, indicating that the company may be on the verge of transitioning into a commercial-stage biotech, with strong growth prospects ahead.
See More
Investment Choices in Gene Editing and Rare Disease Treatments
- Strategic Partnership Advantage: Intellia Therapeutics' deep collaboration with Regeneron accelerates the development of CRISPR gene editing therapies, achieving approximately $67.7 million in revenue for FY 2025, reflecting a nearly 17% year-over-year growth, despite a net loss of about $412.7 million, highlighting both potential and challenges in the high-risk biotech sector.
- Commercial Transition: Omeros has entered the commercial stage with FDA approval of Yartemlea in 2025, reporting no revenue for the fiscal year, yet its partnership with Novo Nordisk offers potential milestone payments and royalties, essential for its long-term revenue strategy.
- Clinical Development Risks: Intellia's nex-z trial is on hold due to a patient death, potentially delaying approvals, while another trial's clinical hold was lifted in January 2026, illustrating the challenges posed by complex intellectual property litigation.
- Market Outlook Comparison: Omeros reported $9.89 million in Yartemlea sales in Q1 2026, with expectations to double revenue in 2027, while Intellia's promising gene editing technology faces higher investment risks due to its early-stage pipeline and ongoing losses.
See More
Intellia Therapeutics Shares Surge 83% Amid Strong Clinical Progress
- Clinical Trial Success: Intellia Therapeutics' lonvo-z demonstrated an 87% reduction in attacks and 62% of patients were attack-free in phase 3 trials, indicating its potential as an effective treatment for hereditary angioedema, which could significantly enhance the company's market position in biotechnology.
- Significant Market Potential: While the market opportunity for lonvo-z is limited, the potential patient population for nex-z targeting ATTR amyloidosis could reach 50,000, and increasing diagnosis rates due to an aging population suggest substantial revenue growth opportunities for Intellia in global markets.
- Strong Financial Position: Intellia ended Q1 with $517.2 million in cash and equivalents and raised approximately $207 million through a secondary stock offering, with management confident that this funding will sustain operations until 2028, bolstering investor confidence in its future growth.
- Notable Risks: Despite the positive outlook from lonvo-z's success, nex-z faced a clinical hold from the FDA due to safety concerns, and the high costs associated with gene-editing therapies may deter insurance coverage, making Intellia's stock a risky investment suitable only for those with a high risk tolerance.
See More
Investor Sentiment Divided in Healthcare Sector
- High Short Interest: As of late June 2026, Intellia Therapeutics (NTLA) and SELLAS Life Sciences Group (SLS) exhibit short interests of 36.01% and 34.06%, respectively, indicating strong bearish sentiment that could pressure stock prices and hinder their ability to raise capital.
- Defensive Stocks Steady: In stark contrast, established pharmaceutical giants like Eli Lilly (LLY) and Johnson & Johnson (JNJ) maintain short interests around 1%, reflecting investor confidence that may help them remain stable amid market volatility, potentially attracting more conservative investors.
- Healthcare Sector Underperformance: Despite a robust 9.55% year-to-date rally in the S&P 500, the Health Care Select Sector SPDR® Fund (XLV) has only gained 2.49%, highlighting the sector's lagging performance which could dampen long-term investor confidence in healthcare stocks.
- Short Interest and Market Dynamics: Hims & Hers Health (HIMS) and Beam Therapeutics (BEAM) show short interests of 29.35% and 28.44%, respectively, suggesting cautious investor sentiment towards their growth prospects, which may challenge their financing and market expansion efforts.
See More
Short Sellers' Dilemma and Opportunities
- Short Seller Focus: There is a divergence in market sentiment regarding short sellers, with some analysts believing certain companies are in trouble while others see them as prime candidates for a short squeeze, reflecting the complexity of market emotions.
- Ondas Acquisition Activity: Ondas Inc. acquired Cyberhawk for $125 million, and although this transaction barely registered on Wall Street's radar, the establishment of its M&A moat could support future growth for the company.
- CleanSpark Risk Assessment: CleanSpark's pivot towards artificial intelligence is viewed as high-risk, leading to insufficient market confidence in its future performance, which may negatively impact its stock price and investor sentiment.
- Vibrant Market Discussion: Investors are actively discussing the pros and cons of short selling in the comments section, showcasing the high level of interest in short trading strategies and the clash of differing viewpoints.
See More
Intellia Therapeutics Advances Gene Editing Treatment with Promising Phase 3 Results
- Clinical Trial Success: Intellia Therapeutics' lonvo-z demonstrated an 87% reduction in attacks during phase 3 trials, with 62% of patients remaining completely attack-free, indicating the treatment's effectiveness in hereditary angioedema (HAE) and potentially significant market opportunities for the company.
- Regulatory Submission Progress: The company has initiated a rolling submission for lonvo-z, aiming to complete it in the second half of the year, and if approved, plans to launch the product in the first half of next year, which could provide a new revenue stream and boost market confidence.
- Optimistic Market Expectations: Wall Street anticipates Intellia's stock price will rise by 70% over the next 12 months, from the current $15.25 to $26, reflecting investor confidence in the company's gene editing technology and its commercialization potential.
- Long-Term Growth Potential: Despite an 80% decline in stock price over the past five years, Intellia's progress with lonvo-z and a second candidate in late-stage trials positions the company to transition into a commercial-stage biotech, opening new avenues for revenue growth.
See More
Intellia Therapeutics Advances Promising New Therapy
- Clinical Trial Success: Intellia Therapeutics achieved an impressive 87% reduction in attack frequency in its phase 3 trial for hereditary angioedema (HAE) with lonvo-z, with 62% of patients remaining completely attack-free during the evaluation period, demonstrating the efficacy and market potential of its technology.
- Regulatory Filing Progress: The company has initiated a rolling submission for lonvo-z, aiming to complete its FDA application in the second half of the year, which will expedite the review process and potentially lead to a market launch in the first half of next year, significantly boosting revenue prospects.
- Optimistic Market Expectations: Wall Street analysts forecast a 70% increase in Intellia's stock over the next 12 months, with a target price exceeding $26, reflecting confidence in the company's technology and product outlook, despite an 80% decline in stock price over the past five years.
- Significant Technological Potential: Intellia's gene editing technology shows promise not only in HAE treatment but also in other serious diseases like transthyretin amyloidosis, indicating that the company may be on the verge of transitioning into a commercial-stage biotech, with strong growth prospects ahead.
See More
Investment Choices in Gene Editing and Rare Disease Treatments
- Strategic Partnership Advantage: Intellia Therapeutics' deep collaboration with Regeneron accelerates the development of CRISPR gene editing therapies, achieving approximately $67.7 million in revenue for FY 2025, reflecting a nearly 17% year-over-year growth, despite a net loss of about $412.7 million, highlighting both potential and challenges in the high-risk biotech sector.
- Commercial Transition: Omeros has entered the commercial stage with FDA approval of Yartemlea in 2025, reporting no revenue for the fiscal year, yet its partnership with Novo Nordisk offers potential milestone payments and royalties, essential for its long-term revenue strategy.
- Clinical Development Risks: Intellia's nex-z trial is on hold due to a patient death, potentially delaying approvals, while another trial's clinical hold was lifted in January 2026, illustrating the challenges posed by complex intellectual property litigation.
- Market Outlook Comparison: Omeros reported $9.89 million in Yartemlea sales in Q1 2026, with expectations to double revenue in 2027, while Intellia's promising gene editing technology faces higher investment risks due to its early-stage pipeline and ongoing losses.
See More
